Amgen's weight-loss drug MariTide has shown promising results in an early trial, keeping the weight off up to 150 days after stopping use. The drug Wegovy, usually taken indefinitely, is being developed by Amgen in a tapered-down version. Additionally, Amgen is testing whether it can wean patients toward lower or less frequent doses of its obesity drug candidate over time. Eli Lilly's weight loss drug Tirzepatide may significantly reduce blood pressure and improve fatty liver disease, as shown in studies. Chegg's Q4 earnings report indicates a decline in subscribers, revenue, and earnings, leading to a drop in stock value. UBS and BP have reported earnings, with UBS experiencing a net loss and BP announcing a share buyback and strong profits. BP's CEO has expressed a pragmatic approach to energy transition and potential growth in oil demand. The company also plans to simplify its business and bring in partners to its solar and LNG portfolio.
The British energy giant BP boosted share repurchases and vowed to make pragmatic investments, in moves to soothe investor concern over its energy transition plans after it posted a forecast-beating earnings of $3 billion in the fourth quarter https://t.co/8N6089TlVY https://t.co/PIhfkk1yu4
Amgen quarterly profit rises 15%, obesity drug trials are on track https://t.co/dMioLEpvtB https://t.co/T9Q58NACVM
Amgen $AMGN expects revenue to jump 20% this year (y/y), beating estimates after acquisition of Hor -Rev $32.4-$33.8bn, est 32.51bn -2024 adj EPS $18.90-20.30, $19.83 -4Q23 $4.71/sh est $4.50 -This was despite a decline in sales of Enbrel
$AMGN | Amgen Q4 Earnings: - EPS $4.71 (Est. $4.62) - Sales $8.20B (Est. $8.13B) - Sees FY24 Revenue $32.4B-$33.8B (Est. $32.66B) - Sees FY24 EPS $18.90-$20.30 (Est. $20.00) https://t.co/5Yvrnps1qr
⚠️ AMGEN QUARTERLY PROFIT RISES 15% AS HORIZON DEAL BOOSTS RESULTS Full Story → https://t.co/to3gPT0qUV
$AMGN 🇺🇸 Amgen Release/ Report https://t.co/3srABSu2Ig Presentation https://t.co/CXphAtI1rn Webcast https://t.co/3srABSu2Ig https://t.co/0C5dQo0EQ5
$AMGN | Amgen Q4 23 Earnings: - Adj EPS $4.71 (est $4.60) - Rev $8.20B (est $8.12B) - Sees 2024 Rev $32.4B To $33.8B (est $32.51B)
Microstrategy, $MSTR earnings: - Revenue: $124.5 million vs $133 million - Says Digital assets now $3.63 billion, up +97% YoY Amgen $AMGN earnings: - EPS $4.71 vs $4.60 - Revenue $8.20 billion vs $8.12 billion Link: https://t.co/Q2LOTrNnz0
BP CEO flags potential to beat 2025 LNG portfolio target of 25 million mt/year https://t.co/OUMwtMVuhE
BP weighs bringing in partners to solar business, says CEO https://t.co/XnqAGmTgzb
Already rolling in diabetes and obesity, Eli Lilly touts tirzepatide's midstage MASH win https://t.co/MEfVcwCnTz
BP report £11BILLION in profit in the last year yet millions of ppl can't afford to turn their heating on. Private shareholders continue lining their pockets at the expense of ordinary ppl. This Govt have paved the way for rampant profiteering at the expense of our communities https://t.co/QtW8PE4Dln
Eli Lilly says weight loss drug shows promise as treatment for fatty liver disease https://t.co/rET1QtndLA
BP’s new boss notched a big win, with the stock soaring on a profit beat and share buyback plan https://t.co/b2Ug8ORnuC
UBS Shares Slide As Earnings Miss Darkens Outlook; CEO Warns 2024 Will Be "Pivotal" https://t.co/d4PzCK8Opa
BP CEO calls for pragmatism on green aims as profits halve https://t.co/4N2oLD7ckN
As our energy bills soared last year, so did the profits of fossil fuel giants like BP, which raked in an £11bn profit - its second highest in the last decade. Instead of rewarding polluters, it's time to make them pay for our green transition to cut energy bills and emissions.
$LLY (+4.9% pre) Lilly Reports Strong Fourth-Quarter 2023 Financial Results and Provides 2024 Guidance - PR https://t.co/wIWkiVGL5b
Eli Lilly reports tirzepatide MASH success during Q4 earnings https://t.co/dC0YMwD4AX
💰 BP has announced annual profits of £11,000,000,000 - second highest in a decade. The money for green investment is there: in the pockets of the super-rich and big polluters. Time to make them pay for a Green New Deal - to bring down emissions and energy bills at once.
Amgen taking different path to weight loss windfall https://t.co/tGAH6gGA7i https://t.co/h5Ey3wtg4b
The blockbuster weight loss and diabetes drug sold by Eli Lilly also appears to improve fatty liver disease, according to early clinical trial data. https://t.co/waDoZbVl53
that potential NASH benefit --> reality based on today's tirzepatide results from @EliLillyandCo entirely unsurprising: obesity leads to NASH, intervention leads to dramatic weight loss, NASH resolves or stabilizes https://t.co/uBngx9tb9D
$LLY set to open at fresh record. Q4 $2.49 eps V $2.22 on $9.35 B revenues +28%, driven by Diabetes/Weight Loss: - Trulicity $1.67 B - Jardiance $798.1 M - Mounjaro $2.2 B despite "intermittent delays in fulfilling some doses" - Zepbound $175.8 M 👀(it was only approved in Nov) https://t.co/AYaKzU8KiS
Eli Lilly rallies toward a fifth straight record close after earnings beat https://t.co/Rj6wsnBmL5
Eli Lilly’s stock surges toward a 5th straight record after an earnings beat and upbeat outlook https://t.co/5jVMYtEomd
BP to simplify business, become more pragmatic, CEO says https://t.co/iH5pJJU9no https://t.co/QJXYmYH2b5
Despite a fall, BP's profits are still - with the exception of last year - the highest since 2012. It’s time to stand up to profit-driven polluters and increase windfall taxation on fossil fuels. Use those funds to invest in public energy and home retrofitting to cut bills. https://t.co/2evNLL8r9h
British #energy giant #BP rebounds into vast profit in 2023, it says, after slumping into a loss the prior year on its exit from Russia following Moscow’s Ukraine invasion. https://t.co/1PDeXCAzgt
BP shares make biggest gains in a year on buyback plan as profit tops estimates https://t.co/9MOQFhpAtD
🔴 BP CEO: I SEE VERY STRONG GROWTH IN OIL DEMAND.
UBS saves over $1 billion by swiftly exiting its Swiss takeover aid package https://t.co/ilIdZv4iwr
"Oil demand [growth] continues to be very strong" - BP CEO | #OOTT
BP will be "pragmatic" about the energy transition, says new CEO Murray Auchincloss | #OOTT $BP
BP to become more pragmatic in investments, CEO says #oott https://t.co/r1bC88xHYz
This Govt’s war on climate action goes marching on. When it’s not promoting drilling for more oil & gas, it’s ditching or delaying the vital green transition. Future generations will pay a terrible price for these climate crimes https://t.co/6N9aiq2glO
BP launches new share buyback despite drop in profits https://t.co/gmhBC3aVvW
UBS Reports Second Quarterly Loss After Credit Suisse Rescue - FT https://t.co/ItrI7Ha4Nb
$BP | BP Q4 23 Earnings: - Adj EPS $17.77 (est $16.27) - Adj Net $2.99B (est $2.76B) - Oper Cash Flow $9.38B (est $8.24B) - Debt Gearing 19.7% (est 19.2%) - Committed To $3.5B Share Buyback For H1 Of 2024 - Announces $1.75B Share Buyback For Q4
UBS reports second quarterly loss after Credit Suisse rescue https://t.co/JBw1FOsFZa
UBS posts second quarterly net loss in a row, but plans to restart buybacks https://t.co/gLZMIlbnbP
UBS beats earnings expectations, announces up to $1 billion share buyback https://t.co/1tQnlCp8JL
UBS Q4 23 Earnings: - Revenue: $10.86B (est $11.29B) - Net Loss: $279M (est $246.2M) - Pretax Loss: $751M (est +$177.1M) - To Resume Share Buybacks With As Much As $1 Bln In 2024
A study of the weight loss drug tirzepatide showed that people who took it had significantly lower blood pressures after 36 weeks of using the medication. https://t.co/XEjfI9TLBZ
Chegg says benefits of its AI push will ‘take time,’ as sales forecast comes up short $CHGG https://t.co/GZKU44wR7T
In an early trial, Amgen's weight-loss drug MariTide was shown to keep the weight off up to 150 days after stopping use https://t.co/o88Rp70HlR via @business
Ed-tech platform Chegg’s stock tumbles on weak Q1 forecast amid pivot to AI https://t.co/guv5TJ63A8
Amgen is testing whether it can wean patients toward lower or less frequent doses of its obesity drug candidate over time. Here's what the early data says. https://t.co/H8KAXgF7a9
Chegg Stock Drops as Forecast Disappoints https://t.co/eukrTrWK3X
Chegg’s stock falls on weak first-quarter forecast as it tries to pivot to AI https://t.co/2Kg1ZALdkE
Chegg earnings call / Q4 and FY 2023 results Subscribers, revenue, earnings - all down YoY in the 6-9% range. https://t.co/NrestWMnMy
Chegg EPS in-line, revenue beat. CEO: "The process of embedding AI into every facet of Chegg’s platform is ongoing and iterative, as we build a truly personalized learning assistant" $CHGG: -7% AH https://t.co/XFrr0wsAxL
$CHGG | Chegg Q4 Earnings: - Adj EPS $0.36 (Est. $0.36) - Sales $188.00 (Est. $187.35M) - Sees Q1 Total Net Revenues $173M-$175M (Est. $180.29M) - Appoints David Longo As CFO, Effective Feb. 21 https://t.co/IgMP8c7oXd
A new weight loss drug is also effective at helping lower blood pressure, a study finds. https://t.co/htAZVwVCBI https://t.co/jrjHkQVcz2
Lilly’s Weight Loss Drug Tirzepatide May Significantly Reduce Blood Pressure, Study Finds https://t.co/s5aQHHjQ6l https://t.co/MLB6gLxwMB
Whilst people were worried sick about skyrocketing energy bills last winter, the government was secretly meeting with BP, which posted record profits off their misery, to ask them which new tax giveaways & subsidies the fossil fuel industry would like. https://t.co/6P4994l6E0
First clinical results for the @Amgen GLP-1 drug for weight loss, which in contrast to others is a dual receptor that blocks GIP https://t.co/gDHkLQiv8O @NatMetabolism https://t.co/nkzhksr8KT
Wegovy is usually taken indefinitely. Amgen wants a version that can be tapered down https://t.co/VV7b6hdPN0 via @elaineywchen for @statnews
$AMGN Wegovy is usually taken indefinitely. Amgen wants a version that can be tapered down https://t.co/af0yASB3td via @elaineywchen
Amgen wants Wegovy-like drug that can be tapered down https://t.co/g8Muih0LQe
In an early trial, Amgen's weight-loss drug MariTide was shown to keep the weight off up to 150 days after stopping use https://t.co/GqjXbBPJJq